Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors
about
Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patientsIsolation of interleukin 2-induced immediate-early genesEvasion from NK cell-mediated immune responses by HIV-1Daclizumab therapy for multiple sclerosisChanges in cytokine levels and NK cell activation associated with influenza.Bovine CD2-/NKp46+ cells are fully functional natural killer cells with a high activation status.Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.Transcriptome analysis reveals similarities between human blood CD3- CD56bright cells and mouse CD127+ innate lymphoid cells.Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cellsRegulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy.CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.Interactions between natural killer cells, cortisol and prolactin in malaria during pregnancy.Therapeutic activity of NK cells against tumors.Ontogeny and expansion of human natural killer cells: clinical implications.Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.Biology of natural killer cells in cancer and infection.CpG methylation changes within the IL2RA promoter in type 1 diabetes of childhood onset.New aspects of natural-killer-cell surveillance and therapy of cancer.Denileukin diftitox: a novel immunotoxin.Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy.A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantationDifferential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis.Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.Rational immunotherapy with interleukin 2.Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy.The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2.Human NK Cell Up-regulation of CD69, HLA-DR, Interferon γ Secretion and Cytotoxic Activity by Plasmacytoid Dendritic Cells is Regulated through Overlapping but Different Pathways.Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro.Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.Differential transcription factor use by the KIR2DL4 promoter under constitutive and IL-2/15-treated conditions.A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.Kinetic analysis of ligand binding to interleukin-2 receptor complexes created on an optical biosensor surface.Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.Expression of a functional c-kit receptor on a subset of natural killer cellsInterleukin 2 receptor gamma chain expression on resting and activated lymphoid cellsInterleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
P2860
Q22254246-BA363966-89CA-409E-A609-1B3F7757B930Q24563249-A7969798-953D-4A92-BBA2-92667749A6C7Q26864489-4C960FF6-60BE-472D-9C8D-05B94F9E35A1Q27022517-0B4AF316-FF94-4421-8BEA-ABA5EC18E4FCQ30407695-AABE7CEA-B855-43CB-B2CE-03669315BE8DQ33241391-D0AA0DB1-7772-4C2A-9EAB-34C02783FBE3Q33346715-0E375982-62DA-411B-85EE-9DCF9139FCB7Q33380148-2E118CE0-CEC8-45AA-B145-F522CCCF549DQ33799561-CFA6032E-84F2-4597-97B6-49A1A74D5268Q33870728-EBC82573-2B00-403F-AD86-AE17A6552AE0Q33992848-3AE4E95E-931E-4FEB-82A9-34891EA348F6Q34067437-AB8D4BC4-CC0B-4E23-8865-FF2D1FCA5726Q34310907-9A4A6DCA-D0D9-466C-A6C8-2DA77A2AA04EQ34537157-AC868AA3-8067-4B8D-8E8B-590612405BC0Q34552162-5EB7C757-6E7D-48DD-8734-78C07B5503C1Q34552167-F098C23D-835B-4A64-8B50-AFC56EF8107DQ34596171-637AD8B1-7EF1-44D7-8805-FCD1C60BBB27Q34651546-634DF0AD-9D05-416C-8D61-D3830BE62F25Q34846677-9E84B6D8-F673-4F72-8AAF-1885966E87D8Q34988265-87E3E30F-44C3-4878-816B-8B0184658ED2Q35007337-ADE4DD39-42BA-4C6B-BF00-B2FEA7029493Q35054508-BB3B4C08-ADC8-4E5C-8369-7492B4BDB12DQ35068749-95A473A8-104F-477C-9A1C-D1CDF31A724FQ35077925-7385B712-8E4A-463D-85CA-8BD47EF9CD79Q35127929-B010F6DA-230F-45A2-9227-110307E34477Q35300674-BA425327-4C53-4574-BF53-ACC78C517F4FQ35353309-86913AA3-E7CD-4468-9C2F-9FD65E007209Q35631979-A4F9F532-C51A-4499-AC18-6797BE7226EEQ35647500-CC9A560A-13AA-4222-9E69-F8FDE8184038Q35760530-031A10D1-05C6-4071-9820-54318210F95EQ35767631-EF3509FA-9E47-43B5-BBDD-32F6509664D5Q35823805-97B700E4-8F6F-484D-AFCA-FEF8E3C503F4Q35903235-ACA39C90-F146-4701-BC8D-DC403DCD90C8Q35976681-B9FAA4AB-078D-44C8-9BB0-BF65122A2681Q36231087-E7B21A63-512A-4421-9AB2-332620D4AAC0Q36279572-4FE39C2C-DFF8-4FB6-92FD-9119A3991B58Q36353604-63D24E21-7A18-4612-A4D2-F2C62B6FC137Q36362347-D3844BB4-F786-4D4F-BE95-601CBC164956Q36363268-1A9D9F8A-0FFC-431A-9342-C4C2DCDF1F04Q36363861-8CCC1D4C-3468-47DC-8C52-E1CBD4E42746
P2860
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Functional consequences of int ...... t with high affinity receptors
@ast
Functional consequences of int ...... t with high affinity receptors
@en
type
label
Functional consequences of int ...... t with high affinity receptors
@ast
Functional consequences of int ...... t with high affinity receptors
@en
prefLabel
Functional consequences of int ...... t with high affinity receptors
@ast
Functional consequences of int ...... t with high affinity receptors
@en
P2093
P2860
P356
P1476
Functional consequences of int ...... t with high affinity receptors
@en
P2093
P2860
P304
P356
10.1084/JEM.171.5.1509
P407
P577
1990-05-01T00:00:00Z